Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) in Multiple Myeloma Patients

NCT00899847 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT00899847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00899847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) in Multiple Myeloma Patients
Lead sponsor
Stanford University
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2009
Completion date
December 31, 2014
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

blood and marrow transplant (bmt), multiple myeloma, transplantation, autologous, transplantation, homologous